

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNITED GENE HIGH-TECH GROUP LIMITED

聯合基因科技集團有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

SUSPENSION OF TRADING

Reference is made to the voluntary announcement of United Gene High-Tech Group Limited (the “**Company**”) dated 15 April 2013 in respect of the commencement of negotiation between the Company and Dr. Mao Yumin (“**Dr. Mao**”) on a possible acquisition (the “**Possible Acquisition**”) of Dr. Mao’s investments in oral insulin related business, including but not limited to the securities of Extrawell Pharmaceutical Holdings Limited (*Stock Code: 858*) (the “**Target Company**”).

On 27 April 2013, the Company entered into a sale and purchase agreement with Dr. Mao (the “**Vendor A**”), a controlling shareholder of the Company, and JNJ Investments Limited (the “**Vendor B**”), which is beneficially owned as to 33.33% by Vendor A, pursuant to which the Company has conditionally agreed to acquire, and (i) Vendor A and Vendor B have conditionally agreed to sell the convertible bonds in an aggregate principle amount of HK\$320,650,000 to be issued by the Target Company and 450,000,000 shares of the Target Company in par value of HK\$0.01 each respectively, at an aggregate consideration of HK\$608,000,000; and (ii) Vendor A has conditionally agreed to sell the convertible bonds in an aggregate principle amount up to HK\$256,520,000 to be issued by the Target Company, at the an consideration up to a maximum of HK\$256,000,000 (the “**Proposed Acquisition**”).

The Target Company, a company whose shares are listed on the main board of the Stock Exchange (Stock Code: 858), is an investment holding company and its subsidiaries are principally engaged in marketing and distribution of pharmaceutical products in the PRC; development, manufacturing and sales of pharmaceutical products in the PRC; commercial exploitation and development of genome-related technology; and development and commercialisation of oral insulin products.

The Proposed Acquisition constitutes a very substantial acquisition and connected transaction of the Company under the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”). The Company is currently in the process of preparing and finalising the announcement in relation to the Proposed Acquisition. The announcement setting out the details of the Proposed Acquisition in compliance with the Listing Rules will be published by the Company as soon as practicable.

SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange will be suspended with effect from 9:00 a.m. on 29 April 2013 pending the release of an announcement in relation to Proposed Acquisition.

By Order of the Board
United Gene High-Tech Group Limited
Lee Nga Yan
Executive Director

Hong Kong, 29 April 2013

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Ms. Lee Nga Yan (executive Director), Dr. Guo Yi (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Dr. Zhang Zhihong (independent non-executive Director) and Mr. Wang Rongliang (independent non-executive Director).